Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis

Scott D. Solomon, Janet Wittes, Peter V. Finn, Robert Fowler, Jaye Viner, Monica M. Bertagnolli, Nadir Arber, Bernard Levin, Curtis L. Meinert, Barbara Martin, Joseph L. Pater, Paul E. Goss, Michael P Lance, Stefanie Obara, Emily Y. Chew, Jonghyeon Kim, Gretchen Arndt, Ernest Hawk

Research output: Contribution to journalArticle

290 Citations (Scopus)

Abstract

BACKGROUND - Observational studies and randomized trials have reported increased cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled randomized studies had limited ability to assess the relationship of either celecoxib dose or pretreatment cardiovascular status to risk associated with celecoxib. Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events. METHODS AND RESULTS - We performed a patient-level pooled analysis of adjudicated data from 7950 patients in 6 placebo-controlled trials comparing celecoxib with placebo for conditions other than arthritis with a planned follow-up of at least 3 years. Patients were administered celecoxib in 3 dose regimens: 400 mg QD, 200 mg BID, or 400 mg BID. From the pooled data, we calculated a hazard ratio for all dose regimens combined and individual hazard ratios for each dose regimen and examined whether celecoxib-related risk was associated with baseline cardiovascular risk. The primary end point was the combination of cardiovascular death, myocardial infarction, stroke, heart failure, or thromboembolic event. With 16 070 patient-years of follow-up, the hazard ratio for the composite end point combining the tested doses was 1.6 (95% CI, 1.1 to 2.3). The risk, which increased with dose regimen (P=0.0005), was lowest for the 400-mg-QD dose (hazard ratio, 1.1; 95% CI, 0.6 to 2.0), intermediate for the 200-mg-BID dose (hazard ratio, 1.8; 95% CI, 1.1 to 3.1), and highest for the 400-mg-BID dose (hazard ratio, 3.1; 95% CI, 1.5 to 6.1). Patients at highest baseline risk demonstrated disproportionately greater risk of celecoxib-related adverse events (P for interaction=0.034). CONCLUSIONS - We observed evidence of differential cardiovascular risk as a function of celecoxib dose regimen and baseline cardiovascular risk. By further clarifying the extent of celecoxib-related cardiovascular risk, these findings may help guide treatment decisions for patients who derive clinical benefit from selective cyclooxygenase-2 inhibition.

Original languageEnglish (US)
Pages (from-to)2104-2113
Number of pages10
JournalCirculation
Volume117
Issue number16
DOIs
StatePublished - Apr 2008

Fingerprint

Celecoxib
Randomized Controlled Trials
Placebos
Safety

Keywords

  • Cardiovascular diseases
  • Cyclooxygenase 2 inhibitors
  • Drugs

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., ... Hawk, E. (2008). Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation, 117(16), 2104-2113. https://doi.org/10.1161/CIRCULATIONAHA.108.764530

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials : The cross trial safety analysis. / Solomon, Scott D.; Wittes, Janet; Finn, Peter V.; Fowler, Robert; Viner, Jaye; Bertagnolli, Monica M.; Arber, Nadir; Levin, Bernard; Meinert, Curtis L.; Martin, Barbara; Pater, Joseph L.; Goss, Paul E.; Lance, Michael P; Obara, Stefanie; Chew, Emily Y.; Kim, Jonghyeon; Arndt, Gretchen; Hawk, Ernest.

In: Circulation, Vol. 117, No. 16, 04.2008, p. 2104-2113.

Research output: Contribution to journalArticle

Solomon, SD, Wittes, J, Finn, PV, Fowler, R, Viner, J, Bertagnolli, MM, Arber, N, Levin, B, Meinert, CL, Martin, B, Pater, JL, Goss, PE, Lance, MP, Obara, S, Chew, EY, Kim, J, Arndt, G & Hawk, E 2008, 'Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis', Circulation, vol. 117, no. 16, pp. 2104-2113. https://doi.org/10.1161/CIRCULATIONAHA.108.764530
Solomon, Scott D. ; Wittes, Janet ; Finn, Peter V. ; Fowler, Robert ; Viner, Jaye ; Bertagnolli, Monica M. ; Arber, Nadir ; Levin, Bernard ; Meinert, Curtis L. ; Martin, Barbara ; Pater, Joseph L. ; Goss, Paul E. ; Lance, Michael P ; Obara, Stefanie ; Chew, Emily Y. ; Kim, Jonghyeon ; Arndt, Gretchen ; Hawk, Ernest. / Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials : The cross trial safety analysis. In: Circulation. 2008 ; Vol. 117, No. 16. pp. 2104-2113.
@article{612b4728e68b4653a8344080daa1659c,
title = "Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis",
abstract = "BACKGROUND - Observational studies and randomized trials have reported increased cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled randomized studies had limited ability to assess the relationship of either celecoxib dose or pretreatment cardiovascular status to risk associated with celecoxib. Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events. METHODS AND RESULTS - We performed a patient-level pooled analysis of adjudicated data from 7950 patients in 6 placebo-controlled trials comparing celecoxib with placebo for conditions other than arthritis with a planned follow-up of at least 3 years. Patients were administered celecoxib in 3 dose regimens: 400 mg QD, 200 mg BID, or 400 mg BID. From the pooled data, we calculated a hazard ratio for all dose regimens combined and individual hazard ratios for each dose regimen and examined whether celecoxib-related risk was associated with baseline cardiovascular risk. The primary end point was the combination of cardiovascular death, myocardial infarction, stroke, heart failure, or thromboembolic event. With 16 070 patient-years of follow-up, the hazard ratio for the composite end point combining the tested doses was 1.6 (95{\%} CI, 1.1 to 2.3). The risk, which increased with dose regimen (P=0.0005), was lowest for the 400-mg-QD dose (hazard ratio, 1.1; 95{\%} CI, 0.6 to 2.0), intermediate for the 200-mg-BID dose (hazard ratio, 1.8; 95{\%} CI, 1.1 to 3.1), and highest for the 400-mg-BID dose (hazard ratio, 3.1; 95{\%} CI, 1.5 to 6.1). Patients at highest baseline risk demonstrated disproportionately greater risk of celecoxib-related adverse events (P for interaction=0.034). CONCLUSIONS - We observed evidence of differential cardiovascular risk as a function of celecoxib dose regimen and baseline cardiovascular risk. By further clarifying the extent of celecoxib-related cardiovascular risk, these findings may help guide treatment decisions for patients who derive clinical benefit from selective cyclooxygenase-2 inhibition.",
keywords = "Cardiovascular diseases, Cyclooxygenase 2 inhibitors, Drugs",
author = "Solomon, {Scott D.} and Janet Wittes and Finn, {Peter V.} and Robert Fowler and Jaye Viner and Bertagnolli, {Monica M.} and Nadir Arber and Bernard Levin and Meinert, {Curtis L.} and Barbara Martin and Pater, {Joseph L.} and Goss, {Paul E.} and Lance, {Michael P} and Stefanie Obara and Chew, {Emily Y.} and Jonghyeon Kim and Gretchen Arndt and Ernest Hawk",
year = "2008",
month = "4",
doi = "10.1161/CIRCULATIONAHA.108.764530",
language = "English (US)",
volume = "117",
pages = "2104--2113",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "16",

}

TY - JOUR

T1 - Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials

T2 - The cross trial safety analysis

AU - Solomon, Scott D.

AU - Wittes, Janet

AU - Finn, Peter V.

AU - Fowler, Robert

AU - Viner, Jaye

AU - Bertagnolli, Monica M.

AU - Arber, Nadir

AU - Levin, Bernard

AU - Meinert, Curtis L.

AU - Martin, Barbara

AU - Pater, Joseph L.

AU - Goss, Paul E.

AU - Lance, Michael P

AU - Obara, Stefanie

AU - Chew, Emily Y.

AU - Kim, Jonghyeon

AU - Arndt, Gretchen

AU - Hawk, Ernest

PY - 2008/4

Y1 - 2008/4

N2 - BACKGROUND - Observational studies and randomized trials have reported increased cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled randomized studies had limited ability to assess the relationship of either celecoxib dose or pretreatment cardiovascular status to risk associated with celecoxib. Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events. METHODS AND RESULTS - We performed a patient-level pooled analysis of adjudicated data from 7950 patients in 6 placebo-controlled trials comparing celecoxib with placebo for conditions other than arthritis with a planned follow-up of at least 3 years. Patients were administered celecoxib in 3 dose regimens: 400 mg QD, 200 mg BID, or 400 mg BID. From the pooled data, we calculated a hazard ratio for all dose regimens combined and individual hazard ratios for each dose regimen and examined whether celecoxib-related risk was associated with baseline cardiovascular risk. The primary end point was the combination of cardiovascular death, myocardial infarction, stroke, heart failure, or thromboembolic event. With 16 070 patient-years of follow-up, the hazard ratio for the composite end point combining the tested doses was 1.6 (95% CI, 1.1 to 2.3). The risk, which increased with dose regimen (P=0.0005), was lowest for the 400-mg-QD dose (hazard ratio, 1.1; 95% CI, 0.6 to 2.0), intermediate for the 200-mg-BID dose (hazard ratio, 1.8; 95% CI, 1.1 to 3.1), and highest for the 400-mg-BID dose (hazard ratio, 3.1; 95% CI, 1.5 to 6.1). Patients at highest baseline risk demonstrated disproportionately greater risk of celecoxib-related adverse events (P for interaction=0.034). CONCLUSIONS - We observed evidence of differential cardiovascular risk as a function of celecoxib dose regimen and baseline cardiovascular risk. By further clarifying the extent of celecoxib-related cardiovascular risk, these findings may help guide treatment decisions for patients who derive clinical benefit from selective cyclooxygenase-2 inhibition.

AB - BACKGROUND - Observational studies and randomized trials have reported increased cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled randomized studies had limited ability to assess the relationship of either celecoxib dose or pretreatment cardiovascular status to risk associated with celecoxib. Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events. METHODS AND RESULTS - We performed a patient-level pooled analysis of adjudicated data from 7950 patients in 6 placebo-controlled trials comparing celecoxib with placebo for conditions other than arthritis with a planned follow-up of at least 3 years. Patients were administered celecoxib in 3 dose regimens: 400 mg QD, 200 mg BID, or 400 mg BID. From the pooled data, we calculated a hazard ratio for all dose regimens combined and individual hazard ratios for each dose regimen and examined whether celecoxib-related risk was associated with baseline cardiovascular risk. The primary end point was the combination of cardiovascular death, myocardial infarction, stroke, heart failure, or thromboembolic event. With 16 070 patient-years of follow-up, the hazard ratio for the composite end point combining the tested doses was 1.6 (95% CI, 1.1 to 2.3). The risk, which increased with dose regimen (P=0.0005), was lowest for the 400-mg-QD dose (hazard ratio, 1.1; 95% CI, 0.6 to 2.0), intermediate for the 200-mg-BID dose (hazard ratio, 1.8; 95% CI, 1.1 to 3.1), and highest for the 400-mg-BID dose (hazard ratio, 3.1; 95% CI, 1.5 to 6.1). Patients at highest baseline risk demonstrated disproportionately greater risk of celecoxib-related adverse events (P for interaction=0.034). CONCLUSIONS - We observed evidence of differential cardiovascular risk as a function of celecoxib dose regimen and baseline cardiovascular risk. By further clarifying the extent of celecoxib-related cardiovascular risk, these findings may help guide treatment decisions for patients who derive clinical benefit from selective cyclooxygenase-2 inhibition.

KW - Cardiovascular diseases

KW - Cyclooxygenase 2 inhibitors

KW - Drugs

UR - http://www.scopus.com/inward/record.url?scp=42449093389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449093389&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.108.764530

DO - 10.1161/CIRCULATIONAHA.108.764530

M3 - Article

C2 - 18378608

AN - SCOPUS:42449093389

VL - 117

SP - 2104

EP - 2113

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 16

ER -